Q-omics provides the consensus-scored BAZ1B profile across patient tissues and cancer cell-line models. BAZ1B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, BAZ1B is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, BAZ1B protein abundance shows 28,650 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, HNSC, and GBM as cancer lineages where BAZ1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BAZ1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BAZ1B survival associations across molecular data types. BAZ1B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BAZ1B RNA expression–survival associations across cancer types. High BAZ1B expression shows unfavorable associations in KICH, MESO, ACC and CESC, but favorable associations in UCS and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for BAZ1B RNA expression.
This table summarizes BAZ1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BAZ1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BAZ1B shows higher tumor expression in HNSC, KIRP, KIRC, COAD, BLCA and LIHC. The HNSC box plot shows higher BAZ1B RNA expression in tumor versus normal tissue (log2 FC = +1.206, t-test p < 0.001).
This table shows molecular features associated with BAZ1B in patient tissues and cancer cell lines. In patient samples, BAZ1B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, BAZ1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
